Tarsus Pharmaceuticals, Inc. Common Stock (TARS) — 分析摘要
Tarsus Pharmaceuticals, Inc. Common Stock（TARS）的市值为2.58十亿美元，最近一年的营收同比增长了+146.7%。净利润率为-14.7%。当前市盈率为-53.4倍。
核心要点
- 营收同比变化+146.7%
- 净利润率-14.7%
- 市盈率-53.4倍
与BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)板块的其他公司相比，TARS的营收增长为+146.7%，市盈率为-53.4倍。
Tarsus Pharmaceuticals, Inc. Common Stock (TARS)
更新 — ET · 市场数据 POLYGON · 财务数据 SEC EDGAR
红旗与风险提示高风险信号
存在多项实质性红旗，在依赖任何估值输出前应先重点核查这些风险。
利息保障倍数为 -5.7x — 盈利不足以覆盖利息支出
最新报表显示自由现金流为负。
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
行业
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
员工人数
370
总部
IRVINE, CA
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。